4 results about "Polar lipids" patented technology

The present invention relates to enzymatic methods for producing a stable lipid-based liquid crystalline phase of Fd3m or Hll space group, compositions comprising such phases, and uses thereof, wherein the starting mixture comprises 30-65 wt% polar lipids and 35-70 wt % oil which are well dispersed and triacylglycerol lipase is added to produce oil hydrolysate which in presence of aqueous solvent results in liquid crystal formation.

The present disclosure provides a method for delivering a nucleic acid cargo to the liver of a subject, the method comprising administering to the subject a lipid nanoparticle encapsulating the nucleic acid and comprising a non-polar lipid. The lipid nanoparticle may exhibit a blebbed morphology, despite the absence or low levels of phospholipid. The disclosure further provides compositions for delivering nucleic acid cargo to the liver in order to treat various diseases, disorders and conditions in the subject.

The present disclosure provides a lipid nanoparticle comprising: nucleic acid cargo; ionizable lipid; non-polar, neutral lipid, such as a phospholipid; non-polar lipid, such as a glyceride; and sterol, the lipid nanoparticle being unshielded and wherein each mol% content is relative to total lipid present in the lipid nanoparticle.

This application relates to compositions comprising polar lipids for maintaining or increasing mobility and vitality. In particular, the invention relates to the use of milk fat globule membrane materials comprising one or more polar lipids in the manufacture of compositions or pharmaceuticals intended for (a) maintaining or increasing lean muscle mass and / or maintaining or decreasing fat mass in human subjects; (b) increasing daily activity and reducing sedentary time in human subjects; and / or (c) after daily administration of the composition or pharmaceuticals for a period of at least three or four months, and wherein the human subjects exercise at least two days per week, compared to the sedentary time and / or low-intensity physical activity time prior to the commencement of daily administration of the composition or pharmaceuticals, a reduction of at least 7 minutes per day in sedentary time and / or an increase of at least 3 minutes per day in low-intensity physical activity time in human subjects.